Implantable devices for resected glioblastoma therapy

Abstract

Glioblastoma (GBM) is a highly infiltrative brain tumor. The treatment of GBM is challenging due to the existence of blood brain barrier, its highly invasive nature, and its heterogeneity. Given the limitations of conventional therapies, this Perspective explores the development trajectory of implantable devices, highlighting the advantages of current models. With the progression in research, these implantable devices certainly hold promising potential for GBM therapy.

Keywords

Biomaterial / Implantable device / Inhibition of recurrence / Prolongation of survival / Resected glioblastoma therapy

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This work was financially supported by the National Natural Science Foundation of China (U23A20591 and 52273158). The figures and tables with " S " before the serial number are included in the Supplementary material.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajps.2025.101034. The figures and tables with " S " before the serial number are included in the Supplementary material.

References

[1] Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: A review. JAMA 2023; 329(7):574-87.

[2] Bastiancich C, Malfanti A, Préat V, Rahman R. Rationally designed drug delivery systems for the local treatment of resected glioblastoma. Adv Drug Deliv Rev 2021; 177:113951.

[3] Padmakumar S, Amiji MM. Long-acting therapeutic delivery systems for the treatment of gliomas. Adv Drug Deliv Rev 2023; 197:114853.

[4] Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, et al. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol 2018; 7(2):CNS08.

[5] Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins Johnathan N, Kim Y, et al. Tissue mechanics promote IDH1-dependent HIF 1 a -tenascin C feedback to regulate glioblastoma aggression. Nat Cell Biol 2016; 18(12):1336-45.

[6] Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: A phase 1 trial. Lancet Oncol 2023; 24(5):509-22.